Vivo Capital related stories
All articles and analysis
Metacrine nabs $65 mln Series CSan Diego-based Metacrine, a developer of therapies for patients with liver, gastrointestinal and metabolic diseases, has raised $65 million in Series C financing. Venrock Healthcare Partners led the round with participation from other investors that included Franklin Templeton Investments, Deerfield Management, Arrowmark Partners, Invus, Lilly Asia Ventures, Vivo Capital, Arch Venture Partners, venBio, Polaris Partners, New Enterprise Associates and Alexandria Venture Investments.
- Poseida Therapeutics snags $30.5 mln Series B
San Diego-based Poseida Therapeutics Inc, which translates gene engineering technologies into cell therapies, has raised $30.5 million in Series B financing. Longitude Capital led the round with participation from other investors that included Vivo Capital, the Tavistock Group and Malin Corporation plc. In conjunction with the financing, Dr. David Hirsch, a managing director at Longitude Capital, has joined Poseida’s board of directors.
- VC-backed Menlo Therapeutics goes public
Menlo Park, California-based Menlo Therapeutics Inc, a pharmaceutical company focused on treating chronic pruritus and chronic cough, has raised $119 million for its IPO after pricing its 7 million shares at $17 per share. The stock began trading January 25, 2018 on the NASDAQ under the ticker symbol "MNLO." Jefferies LLC, Piper Jaffray & Co. and Guggenheim Securities LLC are the lead underwriters. The investors included VenBio, Novo Holdings A/S, Rock Springs Capital, Aisling Capital, Bay City Capital, Vivo Capital, Presidio Partners, Remeditex and F-Prime Capital.
- VC-backed Outpost Medicine hires chief medical officer
Indianapolis and London-based Outpost Medicine, a biopharmaceutical company focused on treating urologic and gastrointestinal disorders, has named Dr. Ian Mills as chief medical officer. Previously, Mills worked at Mitsubishi Tanabe Pharma Europe where he was head of clinical development. Outpost Medicine is backed by Frazier Healthcare Partners, Adams Street Partners, Novo Holdings A/S, Vivo Capital and Takeda Ventures.
- Medeor Therapeutics scores $57 mln Series B
San Mateo, California-based Medeor Therapeutics Inc, a developer of personalized cellular immunotherapies, has raised $57 million in Series B financing. RA Capital Management led the round with participation from other investors that included Sofinnova Ventures, 6 Dimensions Capital, Vivo Capital and WuXi Healthcare Ventures. In conjunction with the financing, Dr. Peter Kolchinsky, a portfolio manager and managing director at RA Capital and Dr. Anand Mehra, general partner at Sofinnova Ventures, have joined the Medeor's board of directors.
- Outpost Medicine rakes in $20 mln
Indianapolis and London-based Outpost Medicine, a biopharmaceutical company focused on treating urologic and gastrointestinal disorders, has raised $20 million in funding. The investors included Takeda Ventures, Frazier Healthcare Partners, Novo Holdings A/S, Vivo Capital and Adams Street Partners. Also, the company has appointed Scott Byrd as president and CEO, succeeding David Socks, interim CEO, co-founder of Outpost, and venture partner with Frazier Healthcare Partners. Socks will remain on the board of directors.
